Pharmaceutical companies are paying thousands of Indiana doctors to talk about GLP-1 drugs, a WRTV Investigation has ...
Novo Nordisk CEO Mike Doustdar said on Tuesday the drugmaker expects headwinds in its international operations in 2026, as ...
Speaking at the J.P. Morgan Healthcare Conference, Doustdar said international markets represent the company's biggest long ...
Oral weight-loss drugs could account for a third or more of the overall GLP-1 market by 2030, a Novo Nordisk executive said ...
Scholar Rock , a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating ...
Wegovy’s oral version of its injectable weight-loss drug is seeing tremendous interest, Novo Nordisk executive Dave Moore ...
Novo Nordisk faces slowing growth, competition, regulatory risks, and Wegovy pricing pressure, with DCF showing fair ...
Novo Nordisk (NVO) downgraded to Hold after FDA GLP-1 actions and 2026 patent cliffs threaten Wegovy supply and growth. See ...
Novo Nordisk’s Wegovy weight loss pill hit U.S. pharmacies this week. Here’s how it works, who qualifies, how to take it, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback